Treats itching of the eye associated with allergic conjunctivitis. ANDA 207411, held by Somerset Theraps LLC. Azelastine Hydrochloride.
As of Nov 16, 2026, ANDA 207411 (Azelastine Hydrochloride), held by Somerset Theraps LLC, was first approved by FDA on Mar 29, 2019, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE: Azelastine hydrochloride ophthalmic solution, 0.05% is indicated for the treatment of itching of the eye associated with allergic conjunctivitis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 29, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Azelastine Hydrochloride0.05% · solution/drops;ophthalmic | Azelastine Hydrochloride | Rx |
| Apr 30, 2021 | Supplement 1Labeling · Standard review | Approved | None posted |
| Apr 30, 2021 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 29, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters